BioLineRx (BLRX) director discloses 2,055,000 option-linked shares

Rhea-AI Filing Summary

BioLineRx Ltd. director Cohen Gal Avraham filed an initial ownership report detailing employee stock options over 2,055,000 underlying ordinary shares. These options carry an exercise price of $0.052 per share and expire on August 14, 2034.

The options were granted on October 1, 2024 under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remaining 1,198,800 scheduled to vest in seven equal quarterly installments, subject to continued service. The filing reflects holdings only and does not report any purchases or sales.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cohen Gal Avraham

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 2,055,000 shares (Direct)

Footnotes (1)

1. Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is October 1, 2024. As of this date, 856,200 options of this grant are vested. The remaining 1,198,800 options will vest in equal 7 quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

Key Figures

Underlying shares: 2,055,000 shares Exercise price: $0.052 per share Expiration date: August 14, 2034 +3 more

6 metrics

Underlying shares 2,055,000 shares Ordinary shares underlying reported employee stock options

Exercise price $0.052 per share Option exercise price for BioLineRx ordinary shares

Expiration date August 14, 2034 Option expiration for reported employee stock options

Grant date October 1, 2024 Grant date of the reported option award

Vested options at grant 856,200 options Vested as of October 1, 2024

Unvested options 1,198,800 options To vest in seven equal quarterly installments

Key Terms

Employee Stock Option (Right to Buy), 2003 Amended and Restated Share Incentive Plan, Section 102 of the Israeli Tax Ordinance, trustee

4 terms

Employee Stock Option (Right to Buy) financial

"security_title: Employee Stock Option (Right to Buy)"

2003 Amended and Restated Share Incentive Plan financial

"Options granted under the 2003 Amended and Restated Share Incentive Plan."

Section 102 of the Israeli Tax Ordinance financial

"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"

trustee financial

"securities issued ... must be registered in the name of a trustee"

A trustee is a person or institution legally appointed to hold and manage assets or enforce an agreement on behalf of other people (beneficiaries). Think of a trustee as a neutral referee or custodian who must act in the beneficiaries’ best interests, follow the trust or contract rules, and handle distributions, recordkeeping and enforcement. Investors care because a trustworthy trustee protects their rights, ensures promised payments or remedies are delivered, and can influence recoveries if things go wrong.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cohen Gal Avraham

(Last) (First) (Middle)

BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	01/01/2025	08/14/2034	Ordinary Shares	2,055,000(3)	$0.052	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is October 1, 2024. As of this date, 856,200 options of this grant are vested. The remaining 1,198,800 options will vest in equal 7 quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

3. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.

	/s/ Gal Cohen	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What did BioLineRx (BLRX) director Cohen Gal Avraham report in this Form 3?

Cohen Gal Avraham reported holding employee stock options linked to 2,055,000 BioLineRx ordinary shares. These options are part of his equity compensation and represent potential future ownership if exercised at the stated price and vesting conditions are met.

What are the key terms of Cohen Gal Avraham’s BioLineRx stock options?

The reported employee stock options have an exercise price of $0.052 per BioLineRx ordinary share and expire on August 14, 2034. They were granted under the 2003 Amended and Restated Share Incentive Plan as part of the director’s compensation package.

How many of the BioLineRx (BLRX) options are vested for Cohen Gal Avraham?

As of the October 1, 2024 grant date, 856,200 of the reported options were vested. The remaining 1,198,800 options are scheduled to vest in seven equal quarterly installments, conditioned on his continued service to BioLineRx at each vesting date.

Does this BioLineRx Form 3 filing show any stock purchases or sales?

The Form 3 filing does not show any stock purchases or sales. It only reports Cohen Gal Avraham’s existing employee stock option position, providing baseline information on his derivative holdings rather than recording new market transactions in BioLineRx shares.

Under which plan were Cohen Gal Avraham’s BioLineRx options granted?

The options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. The filing notes that, to qualify for certain Israeli tax benefits, securities issued under this plan must be registered in the name of a trustee for the employee’s benefit.

Why does the BioLineRx (BLRX) Form 3 mention a trustee for the options?

The filing explains that to receive tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the 2003 Amended and Restated Share Incentive Plan must be held in a trustee’s name. This structure is for tax qualification, not to indicate a transfer of economic interest.